Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin
Authors:
- Pau MontesinosPMPau Montesinos
- Mar TormoMTMar Tormo
- José MaríaJMJosé María
- 28 April 2017
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (7) , 1077-1084
Abstract
Late cardiomyopathy CMP is regarded as a potential severe long-term complication after anthracycline-based regimens for acute promyelocitic leukaemia (APL). We assess by MRI the incidence and severity of clinical and subclinical long-term CMP in a cohort of adult APL patients in first complete remission with PETHEMA trials. Adult patients diagnosed with APL in first complete remission lasting ≥2 years underwent anamnesis and physical examination and were asked to perform a cardiac MRI. Clinical CMP was defined as radiographic and physical signs of heart failure accompanied by symptoms or by left ventricle ejection fraction (LVEF) 2, left ventricle end-systolic volume index ≥38 ml/m2, right ventricle end-diastolic volume index ≥106 ml/m2 and regional wall motion abnormalities. Of the 82 patients enrolled in the study, median cumulative dose of anthracyclines (doxorubicin equivalence) was 650 mg/m2, and median time from APL diagnosis to the study was 87 months (range, 24–195). Seven out of 57 patients with available MRI (12%) had subclinical CMP (all of them showed late gadolinium enhancement in MRI), and none had clinical CMP. Among the 25 patients without MRI, none had CMP by chest X-ray and physical assessment. In summary, we found 12% of subclinical and no clinical late CMP assessed by MRI in APL patients treated with PETHEMA protocols. Due to the low number of patients, we must interpret our results cautiously.Keywords
Funding Information
- Instituto de Investigación Sanitaria La Fe (2012/023)
This publication has 15 references indexed in Scilit:
- Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapyPediatric Blood & Cancer, 2014
- The prominent role of cardiac magnetic resonance imaging in coronary artery diseaseExpert Review of Cardiovascular Therapy, 2014
- Are cardiac Magnetic Resonance Imaging and Radionuclide Ventriculography Good Options Against Echocardiography for Evaluation of Anthracycline Induced Chronic Cardiotoxicity in Childhood Cancer Survivors?Pediatric Hematology and Oncology, 2013
- Screening Adult Survivors of Childhood Cancer for Cardiomyopathy: Comparison of Echocardiography and Cardiac Magnetic Resonance ImagingJournal of Clinical Oncology, 2012
- Subclinical Anthracycline Cardiotoxicity in Patients With Acute Promyelocytic Leukemia in Long‐Term Remission After the AIDA ProtocolCongestive Heart Failure, 2012
- Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline‐induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisionsCancer, 2011
- Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeBlood, 2010
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA groupBlood, 2003
- Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemiaAnnals of Hematology, 2002
- Doxorubicin-Induced CardiomyopathyNew England Journal of Medicine, 1998